More Good News on Melanoma Drug

Researchers from the Vanderbilt-Ingram Cancer Center and other institutions reported more data today on studies of a new melanoma drug that target products of a cancer-causing mutation in the BRAF gene. The study, published in the New England Journal of Medicine, tracked patients with metastatic melanoma who have been followed for more than a year now, on average. More than half of the patients had a response to the drug, and the investigators report median overall survival of almost 16 months.  The drug was approved by the FDA last fall.

These small steps in improving cancer therapies are encouraging to doctors. Johns Hopkins melanoma specialist Evan Lipson, M.D., said the following about today's report:

"The NEJM study is another important step in what is a rapidly changing landscape for melanoma and cancer therapy in general. Some cancers are formed when, inside a cell, a signal is passed from one molecule to another, like a game of telephone. Vemurafenib (Zelboraf) stops that signal from being sent and, in doing so, stops the growth of the cancer. This study provides important information on how likely and for how long the drug will keep the cancer at bay. It’s also a stepping stone to another exciting prospect in cancer research: combining drugs like vemurafenib with other therapies, where two treatments used together might be more effective than each one by itself."

VN:F [1.9.17_1161]
Rating: 0.0/5 (0 votes cast)
No Comments

Leave a Comment

You can use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Johns Hopkins Medicine does not necessarily endorse, nor does Johns Hopkins Medicine edit or control, the content of posted comments by third parties on this website. However, Johns Hopkins Medicine reserves the right to remove any such postings that come to the attention of Johns Hopkins Medicine which are deemed to contain objectionable or inappropriate content. Read our Commenting Disclaimer.

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word

Previous post:

Next post: